Entries by Max

AB‑3028, a Dual‑antigen AND‑gated, TGF‑β–resistant CAR T Therapy

/in , /by

AB-3028 represents a next-generation approach to solid-tumor CAR T therapy tailored to the unique challenges of metastatic castration-resistant prostate cancer. CAR T cells, transformative in hematologic malignancies, have struggled in solid tumors due to heterogeneous antigen expression, on-target off-tumor risks, suppressive cytokines like TGF-β, and chronic stimulation that drives exhaustion. AB-3028 was engineered to counter […]

GenSci143: A Dual-Target ADC Emerging for Metastatic Prostate Cancer

/in , , /by

GenSci143 (aka GenSci-143) is a bispecific antibody-drug conjugate under development for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. The construct targets B7-H3 (CD276) and PSMA simultaneously with a bispecific antibody, coupled via a stable, cleavable linker to a topoisomerase I inhibitor payload, aiming to improve tumor cell killing and bystander effects across heterogeneous […]

Low‑Dose Naltrexone for ADT‑Related Fatigue in Prostate Cancer

/in , , , , /by

A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]

Newsletter 44/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Get ready, folks! I knew I shouldn’t have used up all the best articles last week! This week seems rather poor in comparison, but fear not…the research goes on! Stay strong and fight on! As usual, we also have […]

177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial

/in , , /by

City of Hope Medical Center, in collaboration with the National Cancer Institute, is initiating a randomized phase 1 study in metastatic castration‑resistant prostate cancer (mCRPC) that compares lutetium Lu 177 vipivotide tetraxetan (177Lu‑PSMA‑617 or Pluvicto) alone versus the same radioligand combined with sipuleucel‑T, with the primary goal of quantifying the induced anti‑tumor immune response alongside […]

News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule

/in , /by

A novel dual payload peptide drug conjugate technology, known as the pre|CISION® platform, represents an advance in oncology by delivering two complementary anticancer therapies from a single molecule. This approach leverages the fibroblast activation protein (FAP), which is selectively present in the tumor microenvironment, especially in advanced prostate cancer such as castration-resistant prostate cancer (CRPC). […]

Helicon Degraders Show a New Path in Prostate Cancer Therapy

/in /by

In one of the most compelling advances for prostate cancer biology in recent years, a novel peptide-based degrader has achieved potent, selective elimination of the transcription factor ERG, an oncogenic driver long considered unreachable by medicinal chemistry. The discovery has upended conventional views on druggability in TMPRSS2–ERG fusion–positive prostate cancers, which comprise nearly half of […]

UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer

/in , , , /by

A first-in-human clinical trial conducted at The University of Texas MD Anderson Cancer Center has revealed encouraging early results for HLD-0915, a new oral therapy designed for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that HLD-0915 is well tolerated and […]

Newsletter 43/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Get ready, folks! This newsletter is going to be veeeery long and packed with news. This year too, the ESMO conference brings us plenty of updates, both on clinical trials and on preclinical and observational studies. Stay strong and fight on! […]